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Nitric Oxide (NO)-Independent Modulation of Soluble Guanylyl
Cyclase (sGC) Activity and Function
George L. Britton, M.S.
Advisory Professor: Emil Martin, Ph.D.
Soluble guanylyl cyclase (sGC) plays a key role in the nitric oxide (NO)
signaling pathway, where it functions as an NO receptor and generator of a
secondary intracellular messenger, cGMP. In addition to NO, investigators have
identified a number of proteins that interact with sGC and modulate its function.
For example, the interaction of sGC with ADP-ribosylation factor GTPase
activating protein 1 (AGAP1) governs sGC’s intracellular distribution and
therefore mediates localized production of cGMP. Interactions of sGC with heatshock protein 90 (HSP90) or HSP70 promote the extent of sGC activation upon
NO stimulation, while interaction of sGC with the η subunit of chaperonincontaining T-complex polypeptide 1 (CCTη) or with protein disulfide isomerase
(PDI) decreases NO-stimulated cGMP production. Previous experiments
demonstrated that the G-protein signaling modulator protein, activator of Gprotein signaling 3 (AGS3), attenuates the response of sGC to activators in cell
lysates.
In this report, we provide evidence that sGC activity and responsiveness
are increased in AGS3-deficient mice. We found that AGS3-deficient mice not
only have a lower resting blood pressure than their wild-type counterparts, but
also are more sensitive to sGC agonists (DEA-NO and BAY41-2272).
Hematoxylin and eosin staining of aorta sections did not show any significant no
iii

morphological differences between AGS3-/- and wild type mice. However, sGC in
aortic lysates from AGS3-/- mice generated a higher level of cGMP in response to
the NO-donor, DEA-NO, than in wild type lysates. These data indicate that, in the
absence of AGS3, sGC activity is increased within smooth muscle cells of aortic
tissue. In summary, the data from the present study suggests that AGS3 is a
negative regulator of sGC vascular function.
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INTRODUCTION
1. NO-cGMP Signaling:
In eukaryotic cells, nitric oxide (NO) is a critical diatomic signaling
molecule influencing various physiological processes such as smooth muscle
relaxation, neurotransmission, and platelet aggregation (1-3). Soluble guanylyl
cyclase (sGC) is the primary intracellular receptor for NO-signaling. NO activates,
by several hundred fold, the sGC-mediated conversion of guanine-5’triphosphate (GTP) into the intracellular secondary messenger cyclic guanosine
monophosphate (cGMP) (Fig. 1). Once formed, the second messenger, cGMP, is
responsible for targeting phosphodiesterases (PDE), cyclic-nucleotide gated
(CNG) channels and cGMP-dependent protein kinases (PKG) (4).
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Figure 1. The NO/sGC/cGMP signaling pathway in blood vessels. eNOS catalyzes
the production of NO by conversion of L-arginine to L-citrulline (L-Cit) and NO. NO
diffuses into the smooth muscle cells where it binds to the heme moiety of sGC,
activating the enzyme and increasing cGMP levels. cGMP subsequently binds to and
activates PKG, PDEs, and CNG channels. PKG can promote smooth muscle cell
relaxation by its interaction with many of its downstream effectors, such as
phospholamban (PLB) and myosin light-chain phosphatase (MLCP).
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This report is centered on understanding an alternative method in
regulating sGC function, with primary focus on sGC function in vascular smooth
muscle cells. Therefore, the function of the NO-sGC-cGMP signaling
transduction pathway will be mainly discussed within the context of smooth
muscle cells of the cardiovascular system.
NOS - In mammalian cells, NO is synthesized by a family of nitric oxide
synthases (NOS). Three isoforms of NOS are known, with different tissue
Table 1. Tissue specific expression of various NOS isoforms.

Name

Location

Function

Neuronal Nitric Oxide
Synthase (nNOS)

skeletal muscle
nervous tissue

cell communication

Inducible Nitric Oxide
Synthase (iNOS)

immune system

immune defense

Endothelial Nitric Oxide
Synthase (eNOS)

vascular endothelium

vasodilation

distribution (Table 1) (5). In the cardiovascular system, endothelial NOS (eNOS)
is the main source of NO production and resides in the endothelial layer of the
vasculature (6). Shear forces on the endothelial membrane and/or hormonal
signals binding to endothelial surface receptors cause a surge in intracellular
Ca2+ levels and induce the formation of the Ca2+/Calmodulin complex (7). This
complex leads to subsequent calmodulin (CaM)-dependent activation of eNOS
(8). Thereafter, eNOS catalyzes the oxidation of the amino acid L-arginine to
produce both NO and L-citrulline (9). After its production, NO diffuses across the
endothelial membrane into vascular smooth muscle cells, where it can bind with
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sGC to transmit the NO signal to its various downstream cGMP-dependent
effectors, PKG, PDE, CNG channels (9).
PDE – cGMP is hydrolyzed to GMP by a family of phosphodiesterases, an
enzyme that breaks the phosphodiester bonds of cyclic nucleotides (10).
Collectively, eleven different PDE families and their various splice variants share
common cellular functions: to regulate the duration, localization and magnitude of
cyclic nucleotide signaling (11). The diversity in PDE functions stem from
differences in their structures, cellular localization, expression profiles, kinetic
properties, and inhibitor sensitivities (11). Each PDE isoform demonstrates
distinctive substrate selectivity. For example, PDE5, 6 and 9 are cGMP-selective,
while PDE4, 7 and 8 are cAMP-selective (12). Some PDEs are capable of
hydrolyzing both cAMP and cGMP (PDE1, 2, 3, 10, and 11) (12). PDE inhibitors
are commonly used to maintain intracellular level of cGMP. For example,
sildenafil, a PDE5 inhibitor, is often used as a tool that allows investigators to
quantitate sGC activity from the accumulation of cGMP in response to NO (13).
PKG - The steady state levels of cGMP in the cells as determined by the
relative rates of cGMP formation by guanylyl cyclases and its degradation by
PDE ultimately controls the activation of PKG (4) (Fig. 2). Activated PKG
promotes relaxation of smooth muscle cells. This is achieved through direct
phosphorylation of myosin light-chain phosphatase (MLCP) (14), and the control
of intracellular Ca2+ levels (15). PKG-dependent phosphorylation of MLCP
activates its phosphatase function, which subsequently inhibits smooth muscle
contraction by dephosphorylating myosin light-chain fibers that were
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phosphorylated by myosin light kinase (MLCK). In doing so, the phosphatase
activity of MLCP disrupts the cross-bridge between actin and myosin in the
contracted state, and thus promotes smooth muscle cell relaxation (14). Second,
PKG acts to inhibit smooth muscle contraction by keeping intracellular Ca2+
below the levels that signal the cell to contract (16). This latter effect is
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Figure 2. Possible molecular signaling pathways associated with PKG
mediated smooth muscle cell relaxation. Upon elevated levels of intracellular
Ca2+ derived from the sarcoplasmic reticulum (SR) or the extracellular space,
Ca2+/calmodulin (CaM) complex is formed, which results in the activation of
MLCK. MLCK phosphorylates the myosin light chain fibers signaling the cell to
form cross bridges between actin and myosin. PKG reverses the contracted state
of smooth muscle cells by: 1) activating MLCP; and 2) decreasing intracellular
Ca2+ levels due to sequestration of Ca2+ through SERCA channels located in the
SR, and inhibiting L-type Ca2+ channels, and preventing formation of IP3 by
inhibiting phospholipase C.

accomplished by PKG through several possible mechanisms. These include
phosphorylation of phospholipase C, resulting in reduced generation of inositol
triphosphate (IP3), and phosphorylation of the negative regulatory
phospholamban protein. Phospholamban is associated with the
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sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), and phospholamban
phosphorylation increases the activity of SERCA (15). The overall result of PKG
activity is the decreased availability of intracellular Ca2+ levels in smooth muscle
cells. This restricts the CaM-dependent activation of the myosin-actin cross
bridging enzyme MLCK.
CNG Channels - cGMP is also known to bind to and activate CNG
channels (15). Initially discovered as part of the phototransduction pathway for
retinal photoreceptors, CNG channels also act as nonselective cation channels to
mediate the entry of extracellular Ca2+ into vascular smooth muscle cells (17).
2. Soluble Guanylyl Cyclase
Because sGC lies at the nexus between the beneficial effects of NOsignaling and cGMP-dependent downstream targets, it is an interesting
therapeutic target. Before the function of sGC and its therapeutic potential were
discovered, organic nitrates were commonly used by physicians to treat patients
with angina and heart failure (18,19). It wasn’t until the 1980s that researchers
determined the connection between sGC activation by endogenous NO and
cardiovascular events. To better understand the processes that control and
modulate sGC function, an understanding of sGC structure-function relationships
is needed.
2.1 sGC isoforms and structure
Mammalian sGC consists of one α subunit (73 kDa, 690 aa) and one β
subunit (70 kDa, 619 aa). Two isoforms (α1/α2 and β1/β2) encoded by separate
genes (GUCY1A2, GUCY1A3, GUCY1B2 and GUCY1B3) exist for each sGC
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subunit (20). The α1/β1 heterodimer is the main and ubiquitously expressed sGC
variant, while the α2/β1 heterodimer is expressed primarily in neurons (21).
Pharmacological and biochemical kinetic studies conducted by Russwurm et al.
(22) demonstrated that the naturally occurring sGC isoforms, α1/β1 and α2/β1,
exhibit similar sensitivities to NO despite differences in the primary structure of
the α1 and α2 subunits. Further studies (23) show that the differential biological
effects of the isoforms are based on their localization: α2/β1 has a propensity to
localize at the membrane, whereas the α1/β1 sGC is primarily localized in the
cytosol.
As demonstrated in Figure 3, each sGC subunit is composed of four
domains: an N-terminal Heme-Nitric Oxide/Oxygen (H-NOX) domain, a (PerARNT-Sim) PAS domain, a coiled-coil domain, and a C-terminal catalytic domain
(9).

Figure 3. Structural organization of sGC functional domains. Schematic
representation of sGC domain organization is shown on the left. Known x-ray
structures are shown on the right. Crystal structures of H-NOX, PAS, coiled-coil and
catalytic domains were adapted from Ref [9] with permission from Annual Review of
Biochemistry.
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2.1.1 H-NOX domain
The N-terminal region of sGC is a critical structure that harbors the heme
prosthetic group and provides sGC the ability to sense NO, and to transduce the
message to the catalytic domain. Using a series of α1 N-terminal truncation
mutants of sGC, investigators determined that the NO-sensing heme prosthetic
group resides in the β subunit of the protein (24). For example, spectral,
biochemical, and pharmacological analyses showed that the first 259 amino
acids of the H-NOX domain in α1 could be deleted and still preserve an NOsensitive sGC complex (24). Further spectral and kinetic studies characterized Nterminal fractions of the β1 subunit (25). A fragment containing residues 1-385 of
β1 was found to contain stoichiometric amounts of heme (25). This β1(1-385)
fragment had the same characteristic UV-spectrum and spectral shifts after NO
addition as the full-length heterodimeric sGC (25), indicating that the N-terminus
of β1 is the primary heme-containing domain of sGC. Site-directed mutagenesis
demonstrated that His105 of the β1 subunit coordinates the heme moiety (26).
Subsequent experiments determined that the His105 mutation does not directly
affect heterodimerization of sGC subunits or the function of the catalytic domain
(26). Any substitution of β1His105 abolished heme binding and the capacity of
sGC to respond to NO stimulation (26).
2.1.2 PAS domain
The PAS domain is named after the three proteins in which it was initially
discovered: 1) Per-period circadian protein; 2) Arnt-aryl hydrocarbon receptor
nuclear translocator protein; and 3) Sim-single-minded protein (27). Despite
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differences in their amino acid sequences, PAS domains share a conserved
three-dimensional architecture that functions as a signal sensor (27). In sGC, the
PAS domain appears to perform similarly. Results from a recent study using
hydrogen/deuterium exchange mass spectrometry (HDX-MS) suggested that the
PAS domain of sGC communicates the proximate NO-induced conformational
changes in the H-NOX domain to the catalytic domain (28). HDX-MS analysis
identified NO-dependent perturbations not only within the PAS domain, but also
at the intersection between the PAS and coiled-coil domains (28). Importantly,
these perturbations extend through to the highly flexible coiled-domain domain
and ultimately influence the catalytic domain to reconfigure into an active state
(28).
2.1.3 Coiled-coil Domain
The coiled-coil domain in sGC appears to be unique in that it forms an Shelical structure and, to date, shares little homology with other proteins deposited
in the National Center for Biotechnology Information protein database (29). The
crystal structure of the coiled-coil domain was characterized for the β1 subunit
(residues 348-409) and discovered to form tetrameric arrangements of coiled-coil
dimers. The coiled-coils are likely arranged in parallel, which allows the flanking
sGC domains to align correctly (29). In comparison, anti-parallel coiled-coil
arrangements were shown to form stable, but non-functional, β1 homodimeric
sGC (29). This is likely the result of the improper alignment of the flanking
domains, which prevents the formation of a catalytically active enzyme.
Additional studies have suggested that amino acids Leu394 and Pro399 play
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significant roles in the dimerization and activation of sGC (29).
2.1.4 Catalytic Domain
The catalytic domains of sGC isoforms are not only highly homologous to
one another, but also share a high degree of homology with particulate guanylyl
cyclase and adenylyl cyclase (AC) (15). Therefore, a considerable amount of
knowledge in the function of the catalytic domain of sGC first emerged through
homology modeling with the crystal structure of AC. Investigators found that the
residues used in substrate recognition and catalysis for AC were located on the
cytoplasmic C1 and C2 domains (30). The corresponding domains were
attributed to α1 and β1 of sGC (31). The use of heterologous expression systems
has allowed investigators to confirm these assignments in vitro. For instance,
transient expression of either α1 or β1 subunits alone in COS-7 cells yielded no
sGC activity, whereas co-expression of both subunits produced fully functional
sGC that was responsive to sodium nitroprusside (SNP), an NO-releasing
compound (32). These data indicate that although each subunit contains a
catalytic domain, both α1 and β1 are required to form an active catalytic site.
2.1.5 sGC Architecture
To date, full-length heterodimeric sGC has proven to be resistant to
crystallization, which hampers our understanding of its mechanism of action.
Studies aimed at elucidating the detailed molecular structure of full-length sGC
have had to resort to crystallizing homologous proteins from bacteria, algae, or
work with separate isolated domains. None of these approaches allow
investigators to gain understanding of the structure-function relationship between
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sGC domains. Recent developments in the use of high-throughput single-particle
electron microscopy (EM) has, however, provided a three-dimensional model of a
heterodimeric sGC holoenzyme architecture (33). This approach has provided
some understanding of the higher-order domain architecture of sGC and its
various configurations (33) (Fig. 4A,B). Additionally, it has allowed Campbell et

Figure 4. The flexible coiled-coil domain lends to a unique structure and
function of sGC. (A) The higher-order domain architecture of sGC organized into 2
modular domains with the coiled-coil linking the two halves together. (B) Range of
conformations observed in sGC holoenzyme. 3-dimensional reconstructions are
shown in green, while 2-dimensional images are down below. Model of sGC and its
conformational snapshots were reprinted with permission from Proceedings of the
National Academy of Sciences, Single-Particle EM Reveals the Higher-Order
Domain Architecture of Soluble Guanylate Cyclase, Campbell et al., 2014. Vol. 111
no. 8: 2960-5.

al. (33) to characterize the function of the highly-flexible coiled-coil domain of
sGC. The results showed that the coiled-coil domain is configured in a dimeric
parallel coiled-coil that flexibly bridges two modular ends of sGC. One end
includes the catalytic domain, while the second half consists of a complex formed
between the PAS and H-NOX domains. It appears, that the coiled-coil allows the
two modular ends to freely swing over a continuous range of conformations (Fig.
4B). The degree of flexibility in sGC is demonstrated by the ability of the H-NOX
domain at the N-terminus to contact the C-terminal catalytic domain (33). This
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characteristic flexibility may play an important role in allowing sGC to rapidly and
accurately respond to various cellular signals that modulate its activity.
2.2 sGC Activation
In the basal state, sGC has a relatively low turnover rate of 15-20 min-1(9).
However, upon NO binding to the heme moiety, the enzymatic activity is
increased by ~100-fold to a turnover rate of more than 1800 min-1 (9). Details of
the activation mechanism are currently under investigation. It is well accepted
that NO binds to the heme of sGC to form an unstable 6-coordinate complex,
which rapidly converts into a 5-coordinate complex due to the disruption of the
coordinating bond between His105 and the heme iron (9) (Fig. 5). sGC
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Figure 5. Hypothetical mechanism of
sGC activation. Binding of NO to sGC
heme produces a transient 6-coordinate
complex, followed by disruption of the
coordinating bond between β1 His105
and the heme iron. This results in
formation of the 5-coordinate nitrosylheme and activation of sGC.

containing this 5-coordinate NO-heme complex has a high cGMP-forming
activity. Once NO dissociates from sGC, the production of cGMP falls back to the
basal rate (9). This indicates that sGC activity can be quickly up- and downregulated to ensure proper functioning of NO-dependent signaling processes (9).
It also suggests that the NO-sGC interaction or the subsequent conformational
changes leading to sGC activation may be the subject of regulation by various
exogenous factors.
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3. Exogenous factors affect sGC function:
While NO is the well-established ligand and activator of sGC, a growing
body of evidence suggests that other cellular factors also influence the extent or
the duration of sGC activation. For example, sGC activation by NO is stronger in
the native cellular environment than in vitro, and exhibits a difference in activity
depending on the cells in which sGC is expressed (34). In other studies, it was
demonstrated that the rate of cGMP synthesis is significantly increased in
response to NO stimulus only for a brief period of time. This stimulated state of
intracellular sGC is followed by a quick desensitization, which is not explained by
enhanced PDE activity or decomposition of NO (35). The authors suggested that
intact cells may contain factors that lead to rapid desensitization of sGC.
Investigators have begun to identify several proteins that bind sGC and
modulate its function. Binding of sGC with (1) ADP-ribosylation factor GTPase
activating protein 1 (AGAP1) governs sGC intracellular distribution and therefore
localizes production of cGMP (36); (2) heat-shock protein 90 (HSP90) and
HSP70 increase NO-stimulated sGC activation (37,38); and (3) chaperonincontaining T-complex polypeptide 1, η subunit (CCTη) and protein disulfide
isomerase (PDI) each impede NO-stimulated cGMP production (39,40).
4. LGN and AGS3:
This list of possible sGC interactors and modulators has recently been
updated to include LGN, a protein identified for its 10 leucine-glycine-asparagine
repeats, and its close homolog activator of G-protein signaling 3 (AGS3) (41).
LGN and AGS3 are members of a family of proteins known as receptor-
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independent activators of G-protein signaling (AGS) (42). Initially discovered in a
yeast-based functional screen as a factor involved in promoting G-protein
signaling independent of a G-protein coupled receptor, AGS proteins are now
known to influence the processing of cellular signals by acting as alternative
binding partners for G-protein subunits (42). Over the past decade, a confluence
of biochemical data has put various AGS proteins into three groups, based upon
the mechanism of interaction with G-proteins (43). Group 1 AGS proteins
function as guanine nucleotide exchange factors (GEF) and therefore increase
G-protein signaling turnover rates (43). Group 2 AGS proteins act as guanine
nucleotide dissociation inhibitors (GDI) and impede Gαi-protein signaling (43).
Group 3 AGS proteins interact with Gβγ, but their functions are not yet well
understood (43). Both LGN and AGS3 belong to group 2 of AGS proteins (43).
These proteins have a 3-module domain organization and share 59% amino acid
sequence homology. As shown in Figure 6, the N-terminal domain containing
seven tetratricopeptide repeats (TPR) is separated by a linker region from a Cterminal GoLoco domain that contains four G-protein regulatory (GPR) motifs
(41,44). Recent evidence indicates that each GPR motif binds and stabilizes one
Gαi in the GDP-bound conformation. It has been suggested that AGS3 and LGN

Figure 6. Similar organization of AGS3 and LGN proteins. Both LGN and
AGS3 have 7 tetratricopeptide repeats (TPR) at their N-terminal domain, and 4 Gprotein regulatory (GPR) motifs at their C-terminal GoLoco domain.
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may serve as scaffolding proteins within a larger signaling complex (42,45).
These discoveries have broadened the perspectives on the role of G-protein
signaling.
It is now understood that LGN directly interacts with sGC (46). Yeast twohybrid screens against α1 or β1 sGC as baits identified LGN as a possible sGC
interactor (46). The sGC-LGN complex was co-precipitated from cultured cells
and tissue homogenates. A series of co-immunoprecipitation studies using
purified full-length and truncated isoforms of LGN and sGC indicate that the TPR
domain of LGN and the catalytic domain of sGC are required for the interaction
(46). The effects of this interaction were later examined in experiments
monitoring the activity of sGC when LGN is either overexpressed or knockeddown. The results showed that LGN overexpression resulted in lower sGC
activity in cellular lysates, whereas knockdown of LGN transcription mediated
higher sGC activity (46). Collectively, these in vitro data suggest that LGN is a
negative modulator of both the basal and activated states of sGC (46). The
homologous AGS3 protein was also shown to inhibit sGC, but with more effect
on activated sGC. In other studies performed by Blumer et al (47), mice lacking
AGS3 had a NO-dependent drop in mean arterial blood pressure that was
considerably longer than in wild-type counterparts. These studies suggest that
AGS3 may function as a possible component in the molecular processes that
alter sGC activity in the NO/cGMP signaling pathway
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AIMS
The main goal of my study was to investigate how AGS3 affects sGC
function. I hypothesized that, similar to LGN, AGS3 acts as a negative modulator
of sGC, and that AGS3 deficiency should result in increased sGC activity in vivo.
To test this hypothesis, I pursued the following specific aims:
1) Determine the effect of AGS3-deficiency on sGC-mediated regulation
of blood pressure; and
(2) Determine the effect of AGS3-deficiency on sGC activity in tissue
extracts.
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METHODS:
Mice:
All animal manipulations were approved by the Animal Welfare Committee
at the University of Texas Health Science Center at Houston. C57BL/6 wild type
mice were purchased from Harlan Laboratories, Inc. AGS3 null mice were
obtained from the laboratory of Dr. Stephen Lanier at the Medical University of
South Carolina. Wild type and AGS3-null mice were housed in separate cages at
the University of Texas Health Science Center’s Animal Core Facility in a
controlled environment: 12-h light/12-h dark cycle; 22°C; and free access to
water and food. Body weight (25-28 grams) for each mouse was assessed prior
to blood pressure measurements.
Genomic DNA Isolation:
Genomic DNA was extracted and isolated from ear samples of AGS3 -/and wild type mice using a DNeasy kit (Qiagen). Tissue samples were
transferred quickly to a microcentrifuge tube containing a premixed solution of
180 µl of “ATL” Buffer (proprietary) and 20 µl of proteinase K provided by Qiagen,
mixed thoroughly by vortexing for 20 seconds, and subsequently incubated at
56°C overnight to ensure complete tissue lysis. The next day, each tube was
vortexed for 15 seconds and 200 µl of “AL” buffer added. Again, samples were
vortexed for 15 seconds, before adding 200 µl of ethanol to each tube. Genomic
DNA was isolated using Qiagen filter columns following the company protocol.
Each wash was removed by centrifugation at 6000 x g for 1 minute. DNA was
then eluted with 50 µl of sterile water.
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Amplification of Genomic DNA by PCR:
Genomic PCR was used to detect the deletion of exon 3 in the AGS3
gene of AGS3-/- mice. The following primers were used for this purpose: forward
(5’-TCA GAG CCA TCC TGA CTG CAT AGA-3’) and reverse (5’-TGA TTG CAG
GAG CTG TGT TCT AGT-3’). 250 ng of genomic DNA was mixed with a master
mix containing: 2.5 µl of 10x Taq Buffer (Fisher), 2 µl of 2.5 mM dNTP mix, 2 µl of
10 µM forward primer, 2 µl of 10 µM reverse primer, 0.25 µl of Taq polymerase
(5000 units/ mL) (Fisher), 12.75 µl of water, and 1.5 µl of 2 mM MgCl2. PCR was
performed using the following cycling conditions: 94ºC, 120 seconds; followed by
35 cycles of 94ºC for 30 seconds, 60ºC for 60 seconds and 72ºC for 45 seconds.
Following PCR, samples were analyzed by electrophoresis in a 3% agarose gel.
Mean Arterial Blood Pressure Measurements:
The CODA tail-cuff system (Kent Scientific, Boston MA) was used in all
blood pressure recordings. This system uses Volume Pressure Recording (VPR)
to non-invasively measure changes in blood pressure. Wild type and AGS3 -/mice were acclimated to the experimental conditions and equipment for 3 days
prior to recording data. Each mouse was comfortably restrained in the provided
animal holder, and safely positioned on a warming plate for at least 15 minutes to
maintain a body temperature of 32- 35°C. During this time, the occlusion cuff
(OC) and VPR cuffs were threaded together at the base of the tail and secured in
a comfortable position to minimize discomfort for the mouse. Mean arterial blood
pressure (MABP) was determined from the CODA-designed VPR and occlusion
cuff by measuring the total blood volume in each tail from conscience mice. At
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the conclusion of each experiment, mice were immediately removed from the
holder and returned to their cages. Blood pressure recordings were acquired by a
central CODA controller and data collector for further analysis.
Resting Mean Arterial Blood Pressure Measurements:
Resting MABP was evaluated in AGS3 -/- and wild type (n=8)
preconditioned mice using the CODA tail-cuff system as described above. Both
animal groups experienced 10 acclimation cycles prior to recording the MABP.
Blood pressure measurements were recorded at 36-second intervals over 36
minutes.
Effects of sGC Activator Administration on MABP:
To evaluate the effects sGC agonist have on vasomotor control in AGS3 /- (n=16) and wild type (n=10) animals, mice were randomly divided into two
treatment groups: (1) one intraperitoneal (IP) injection of a NO-donor, 2-(N,Ndiethylamino)diazenolate-2-oxide, diethylammonium salt (DEA-NO; 80 μg/kg;
Cayman Chemical); or (2) one IP injection of an NO-independent sGC allosteric
activator (BAY41-2272; 200 μg/kg; Cayman Chemical). MABP was recorded in
both treatment groups in preconditioned mice using the CODA tail-cuff system.
Baseline blood pressure changes following IP injection of sterile PBS (200 μl)
were recorded for 20 minutes prior to the injection of sGC agonist. Injections
were made through a hole drilled in the animal holder. Following the IP injections
of agonists, blood pressure was recorded at 36-second intervals over a period of
20 minutes.
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Tissue Homogenate Preparation:
The descending aorta from wild type or AGS3 -/- mice was surgically
removed, homogenized in a glass-glass conical tissue grinder and sonicated in
an ice bath for 16 seconds total with 4-second pulses. To separate residual
tissue debris from cellular lysate homogenates were centrifuged at 5,000 x g for
15 minutes at 4 °C. Supernatants were subsequently centrifuged at 100,000 x g
for 1 hour at 4°C to separate the membrane fraction (pellet) from the cytosolic
fraction. Each fraction was placed into a separate microcentrifuge tubes and
stored at -80 °C for later use. Sample protein amounts were determined by the
implementation of a Bradford assay. Absorbance values from a dilution-series of
unknown samples are interpolated onto a plot for the standard (bovine serum
albumin) to determine sample protein concentrations.
Phosphodiesterase Activity:
To measure total tissue PDE activity, [α-32P] GTP was first converted to
[α-32P] cGMP by reacting with purified sGC at 37 °C in reaction buffer (4 mM
MgCl2, 0.05 mg/ml creatine kinase, 5 mM phosphocreatine,125 mM triethanol
amine (TEA), and 1 mM dithiothreitol (DTT)). Reactions were stopped by briefly
heating the samples at 100 °C. The reaction product, [α-32P] cGMP, was used as
substrate to measure PDE activity in mice aortic lysates with or without a
nonspecific PDE inhibitor, IBMX (1 mM) or a PDE5 specific inhibitor, Sildenafil
(200 μM). All reactions were incubated in a 37 °C water bath for 15 minutes and
heat inactivated at 100°C for 3 minutes. Samples were then centrifuged for 5
minutes at room temperature to pellet the precipitated proteins. An aliquot of
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each supernatant (10 µl) was then analyzed by thin layer chromatography (TLC)
on a pre-washed polyethyleneimine cellulose plate in a solvent system containing
equal volumes of 0.5 M of ammonium acetate (pH 6) and 0.5M of ammonium
formate (pH 4). [α-32P] GTP alone with reaction buffer, or in the presence with
purified sGC were used as controls to determine cGMP and GTP migration
position The bands corresponding to substrate and product were visualized by Xray film autoradiography overnight at -80 °C, and quantified by densitometric
analysis using NIH ImageJ software.
sGC Activity Assay:
Soluble guanylyl cyclase activity in aortic lysates was assayed in the
presence or absence of 100 μM NO donor DEA-NO by the formation of [α-32P]
cGMP from [α-32P] GTP. Following tissue lysate separation by centrifugation, 20
μl of aortic tissue supernatants were mixed with 10 μl of reaction buffer (125 mM
TEA, 250 μM EGTA, 10 mM IBMX, 4 mM MgCl2, 0.05 mg/mL creatine kinase, 5
mM creatine phosphate, 1 mM DTT, 100 μM GTP, 500 μM GTP/0.08 μCi of [α32

P] GTP). After incubating at 37°C for 10 minutes, reactions were stopped by

heat-inactivation for 3 minutes at 100°C. Reaction products were separated and
quantified by TLC, as described above.
Western Blots:
Tissue lysate proteins were separated by SDS/polyacrylamide gel
electrophoresis (8% gels) and transferred to PVDF membranes. Membranes
were blocked with 5% milk containing 0.1% Tween-20 for 30 minutes and
incubated with the desired primary antibody for 2 hours at room temperature or
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overnight at 4 °C. Primary antibodies were: anti-α1 polyclonal antibodies (Sigma
Aldrich, catalog # G4280) (1:1000 dilution); anti-LGN goat polyclonal antibody
(AbCam, catalog # ab84571) (1:1000 dilution); and anti-α-actin polyclonal
antibody (Sigma Aldrich, catalog # SAB2500963) (1:2000 dilution). For detection
of β1, polyclonal antibodies raised in rabbits against the SRKNTGTEETKQDDD
peptide of human sGC β1- subunit conjugated to KHL were used (1:500 dilution).
Membranes were then washed three times for 10 minutes with 1X Tris Buffered
Saline with Tween-20 (TBS-T). The horseradish peroxidase-conjugated
secondary antibodies were used at dilutions of 1:3000 (anti-mouse, Sigma
catalog # MFCD00162644) or 1:5000 (anti-rabbit, catalog # MFCD00162788;
and anti-goat, catalog # MFCD00162340) dilutions. Membranes were then
washed three times with TBS-T for 10 minutes. Immunoreactive bands were
visualized on Kodak Biomax X-ray film by enhanced chemiluminescence (ECL
Plus, GE Healthcare). Densitometric analysis was performed using NIH ImageJ.
Probed proteins were normalized to either α-actin from smooth muscle cell
samples, or β-actin from lung samples.
Histology/Autofluorescence:
Descending aortas from AGS3 -/- and wild type mice were quickly
removed following cervical dislocation, embedded in optimal cutting temperature
compound (OCT) by flash freezing in liquid nitrogen and stored at -80°C. Frozen
samples were serially cut into 5 μm sections using a Microm 505E cryostat and
transferred to microscope slides. Each specimen was dehydrated in 95% ethyl
alcohol solution for 30 seconds, briefly rehydrated by submerging in water for 10
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seconds and then stained with Shandon Gill 3 Hematoxylin (Thermo Scientific)
for 4 minutes. The stained specimens were then dehydrated again by dipping in
increasing concentrations of ethyl alcohol in water, cleared using Shandon Bluing
Reagent (Thermo Scientific) for 1 minute and counterstained with Shandon Eosin
Y Cytoplasmic Counterstain (Thermo Scientific) for 30 seconds. Again, each
specimen was serially dehydrated in increasing concentrations of ethyl alcohol
and then fixed in Histo-Clear (National Diagnostics). Sections were imaged under
a light microscope to assess lumenal cross sectional area. A Nikon ECLIPSE Ti
fluorescence microscope with a CoolSNAP photometrics camera was used to
assess elastin deposition (48).
RNA Isolation /Real-Time Quantitative RT-PCR:
Total RNA was isolated from aortic tissue using Ambion’s RiboPure kit.
Tissues were harvested from AGS3 -/- and wild type mice, snap frozen in liquid
nitrogen, and ground to a fine powder with a chilled mortar and pestle. Ground
tissue samples were collected, reconstituted in Ambion’s proprietary “TRI”
reagent, subjected to 5 rounds of freeze/thawing, and centrifuged at 12,000 x g
for 20 minutes at 4 °C. RNA was isolated from the supernatants by adding 200 μl
of chloroform and centrifuging at 12,000 x g for 15 minutes at 4° C. RNA was
precipitated from the aqueous layer by addition of 200 μl of 100% ethanol,
collected by centrifugation, transferred to Ambion’s provided filter columns, and
finally eluted with 40 μl of sterile water. Purified RNA was stored at -80 °C.
cDNA Synthesis:
cDNA was synthesized in thin-walled PCR tubes by mixing 2 μg of total
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RNA with 10 μl of RT master mix consisting of: 2 μl of 10x RT buffer, 2 μl of 10x
random hexamers, 0.8 μl of 100 μM dNTP, 1 μl of RNAse inhibitor, 1 μl (200
units) of Superscript reverse transcriptase and 3.2 μl of water. The reaction
mixture was incubated at 37° C for 150 minutes.
qRT-PCR:
Eight μl of PCR master mix (400 nM forward and reverse primers (IDT,
Coralville, IA), 100 nM fluorogenic probe (Biosearch Technologies, Novato, CA),
5 mM MgCl2, 200 μM deoxynucleotides, PCR buffer, and 1.25 units of Taq
polymerase (Invitrogen) were added to wells of a 96-well plate containing 2 ul of
each synthesized cDNA. Each 96-well plate reserved wells for an 18S probe as a
standard for data normalization, and a no-template control well for each probe to
account for non-specific fluorescence. All reactions were performed in triplicate
using the following cycling conditions in a Mastercycler ep realplex real-PCR
system (Eppendorf): 95 °C, 1 minute; followed by 40 cycles of 95 °C, 12
seconds, and 60 °C, 30 seconds.
Statistical Analysis:
Results are expressed as mean ± SD, unless indicated otherwise. Oneway analysis of variance, followed by Turkey’s post-hoc test was used for
comparisons of hemodynamic time-course following DEA-NO and BAY41-2272
treatments. P <0.05 was considered significant.
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RESULTS:
I hypothesized that AGS3 acts as a negative modulator of sGC, and that
an absence of AGS3 should increase sGC activity and function in tissues. To test
this hypothesis I used an AGS3-defecient mouse model that was made available
to us by Dr. Stephen Lanier at the Medical University of South Carolina. A
knockout mouse line allows the investigator to better understand the role of the
missing gene product by noting any phenotypic deviations compared to wild type
mice, and by corroborating these observations with biochemical assays. In our
case we thought that it was important to obtain an AGS3 knockout mouse line as
a means to elucidate the changes of physiological and biochemical function of
sGC in native tissues. With permission from Dr. Stephen Lanier, an AGS3-null
mouse colony was established and maintained at the University of Texas Health
Science Center’s Animal Core Facility. Before evaluating the changes in sGC
activity and function that may be caused by the lack of AGS3 protein, we
confirmed the knockout of the AGS3 gene in the mice that were bred in our
Animal Facility. As shown in Figure 7, genomic PCR confirmed the deletion of
exon 3 of AGS3-/-.
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Figure 7. PCR genotyping of AGS3-/mice. The
band was
amplified from a WT mice ear sample,
whereas the KO mouse sample
exhibited instead a single 310-bp band,
reflecting the loss of exon 3.

wild type (565-bp) (KO) and wild type
AGS3-/- (310-bp) expected 565-bp WT

WT KO
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LGN/AGS3 – Since previous studies demonstrated that LGN and AGS3
proteins have similar effects on sGC function in vitro, we set out to test whether
LGN might be up regulated to compensate for the lack of AGS3 protein in AGS3/-

mice. Therefore, a Western blot analysis was used to assess the levels of LGN

in lung and aortic tissue from AGS3-/- and wild type mice. As shown in Figure 8,
we found equivalent amounts of LGN in lung tissue for both wild type and AGS3-/mice. However, we found no LGN signal in aortic tissue. This observation is
consistent with the studies by the Lanier group, who evaluated the expression of
LGN and AGS3 in a variety of mouse tissues (49). They found that the two
proteins are differently expressed between tissues. Results in Figure 8 suggest
that LGN expression was not increased in AGS3-deficient mice. A similar

Figure 8. Expression of LGN protein is
not detected aortas and is not
increased in AGS3-/- mice. Lung and
aortic tissue from wild type and AGS3-/mice
were
homogenized
and
immunoblotted for the presence of LGN
in cytosolic fractions.

conclusion can be drawn from results of RT-qPCR assays probing for AGS3 and
LGN in aortic tissue samples from AGS3-/- and wild type mice (Fig. 9). LGN
transcript levels were roughly equal between AGS3-/- and wild type mice (Fig.
9B). The lack of compensatory changes in LGN in aorta of AGS3-/- mice suggests
that aorta may be a good tissue to investigate the effects of AGS3 knockout on
the function and activity of sGC. Additionally, RT-qPCR was able to confirm that
the level of AGS3 transcript in aortic tissue samples of AGS3-/- mice was only 4%

-25-

of that in its wild type counterpart (Fig. 9A). In summary, we confirmed the AGS3/-

knockout at the gene and transcript level. Moreover, we demonstrated a lack of

compensatory expression of homologous LGN protein in the aorta, ruling out
functional redundancy.

Figure 9. Comparison of LGN and AGS3 transcript level in AGS3-/- and wild type
mice aorta lysates. The levels of AGS3 and LGN transcripts were determined by qRTPCR and normalized to 18S ribosomal RNA to obtain CT values, where CT = CTAGS3-/– CT18S. Relative fold change in transcript levels for AGS3 (A) and LGN (B) were
calculated based on CT values, where CT = CTAGS3-/- -CTWT. Dashed line across
graph demarcates equal transcript levels between AGS3-/- and wild type. Data
represented as Mean ± SD (n=3)
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Aim1: sGC Dependent Regulation of Blood Pressure in AGS3-/- Mice
To assess the effects of AGS3-deficiency on sGC-mediated regulation of
blood pressure, we measured hemodynamic changes in wild type and AGS3-/mice in response to NO-dependent and NO-independent sGC activators. First,
we evaluated the resting blood pressure of both AGS3-/- and wild type mice. As
shown in Figure 10, we found that AGS3-/- mice have a lower resting blood
pressure in AGS3-/- mice than in wild-type counterparts. This observation is in
line with previous results by Blumer et al, who recorded a 117 mmHg MABP for
wild type mice and a 107 mmHg MABP for AGS3-/- animals (47).

Figure 10. AGS3-/- mice exhibit lower resting mean arterial blood pressure
(MABP) compared to wild type mice. MABP in wild type and AGS3-/- mice was
monitored over a 36-minute period. Data presented as mean +/- SD (n = 10, WT; n
= 16, AGS3-/-); *p <0.05.

Hemodynamic response to sGC activators - Next, blood pressure changes
in wild type and AGS3-/- mice were monitored following IP-administration of two
different sGC activators. First, we recorded the changes in blood pressure
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following injection of DEA-NO, a chemical compound that releases NO while in
circulation and mimics the endogenous production of NO. MABP changes were
monitored over a 20-minute period to detect the maximal change in blood
pressure, and the time required for restoration of blood pressure. As shown in
Figure 11, AGS3-/- mice initially responded with a slightly larger, but not
statistically significant, decrease in blood pressure following DEA-NO
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Figure 11. sGC-dependent vasomotor function is elevated in AGS3 animals
following DEA-NO administration. (A) Changes in MABP in AGS3-/- and wild type
mice following a single DEA-NO (80 g/kg) IP injection. MABP was non-invasively
measured using the CODA system (Kent Scientific). (B) Maximal change in MABP
following DEA-NO injection. (C) Time required to restore 80% of MABP following
DEA-NO injection. Data are presented as mean+/- SE (n = 7). * p < 0.01.
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administration compared to wild type mice (Fig. 11A, B). We observed that
AGS3-/- mice maintained the decreased blood pressure much longer than the
wild type controls (Fig. 11A, C). We also probed the mice with an NOindependent sGC activator, BAY41-2272. The use of an NO-independent sGC
activator allows us to determine if the effects of DEA-NO may be attributed to
sGC-independent effects of NO. The results presented in Figure 12 indicate that
AGS3-/- mice experience a much larger decrease in the MABP (Fig. 12B), and
require longer times to restore MABP to initial values (Fig. 12C). In conclusion,
the sGC-dependent decreases in blood pressure by BAY41-2272 and by NO
were more pronounced in AGS3 deficient mice.
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Figure 12. sGC dependent vasomotor function is elevated in AGS3-/- animals
following BAY41-2272 administration. (A): Changes in blood pressure in AGS3-/- and
wild type mice following a single IP injection of BAY41-2272 (200 µg/kg). MABP were
non-invasively measured using the CODA system. (B) Maximal change in the MABP
following BAY41-2272. (C) Time required to restore 80% MABP following BAY41-2272.
Data are presented as mean +/- SE (WT n = 10; AGS3-/- n = 16). *p<0.01.
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Histology of Blood Vessels - To check whether the differences between
the mouse strains might have been a result of vascular anatomical variations
between AGS3-/- and wild type mice, descending aortas from each strain was
excised and sectioned for H&E staining and autofluorescence detection. H&E
staining allowed proper distinctions to be made between smooth muscle and
adventitia of the vessel, which allowed cross sectional area quantifications to be
made for the lumen and the media layer containing vascular smooth muscle
cells. This provided a means to separately measure lumenal and whole vessel
cross sectional areas for each section. The data was normalized by calculating a
ratio of the cross sectional areas of the lumen and the whole vessel (Fractional
lumen cross section). The fractional lumenal cross sections in AGS3-/- and wild
type mice were roughly similar (Fig. 13A and B).
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Figure 13. Wild type and AGS3-/- mice blood vessel structure. (A) Four sections
per mouse (n=6) were stained with H&E to visualize the anatomy of blood vessels (left
panels). Four sections per mouse (n=6) were used to assess the extracellular matrix
in the vascular wall by monitoring the autofluorescence of elastin (right panels). (B)
Fractional luminal sectional area was determined from H&E sections by taking the
ratio of the luminal area in the section to the area of the whole vessel. Data is
presented as mean +/- SD based on 24 sections from 6 mice per group (n=24).
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An elevated deposition of the extracellular matrix may significantly affect
the vasorelaxing properties of blood vessels (48). Therefore, we also assessed
the deposition of extracellular matrix in the aortas of AGS3-/- and wild type mice.
We took advantage of the autofluorescence of elastin in the vascular tissue to
assess whether significant changes in matrix structure or amount occurred due to
AGS3 deficiency. As shown in Figure 13A (right panels), images acquired with a
FITC filter did not reveal any differences in matrix structure or amount between
wild type and AGS3-/- mice. These data on lumen and matrix dimensions allowed
us to conclude that there were no gross distortions in the structural elements in
the vessels that may directly affect the vasomotor function in AGS3-/- mice.
Previous studies demonstrated that totally sGC deficient mice develop
hypertension (50). Moreover, mice that lack sGC only in vascular smooth muscle
cells also develop hypertension (50,51), indicating that sGC-dependent
regulation of blood pressure is contributed predominantly by the vascular smooth
muscle cells. Thus, the data presented above suggest that changes in the
hemodynamic parameters in response to sGC agonists in AGS3-/- mice may be
attributed to changes in sGC vasomotor function in the vascular bed.
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Aim2: sGC activity in AGS3-/- mice
The main goal of this aim was to determine if sGC activity was changed in
the aortic tissue of AGS3-/- mice. Before directly testing this hypothesis, we set to
rule out some processes that may indirectly affect the activity of sGC in AGS3-/mice including changes to the PDE activity and altered sGC expression.
PDE Activity - Decreased PDE-dependent hydrolysis of cGMP may
significantly enhance the vascular response to sGC targeting agents without
affecting sGC activity. Thus, we assessed whether the absence of AGS3
expression altered PDE activity. Aortic tissue lysates from AGS3-/- and wild type
mice were incubated with [32P] cGMP, as described in Methods. The
representative chromatogram in Figure 14A illustrates the procedure for
quantitating PDE activity in lysates with or without a PDE inhibitor. The reaction
product [32P] GMP was separated from the substrate [32P] cGMP using TLC, as
described in Methods. The intensity of the [32P] GMP was quantified by
densitometry to determine the amount of generated GMP. We found that similar
amounts of AGS3-/- lysate produced ~50% more [32P] GMP than the wild type
lysates, indicating an elevated PDE activity in the AGS3-/- tissue (Fig. 14A). The
use of PDE inhibitors allowed us to confirm that the observed conversion of
cGMP to GMP was due to PDE activity. Figure 14B shows the rate of GMP
formation in the presence of PDE5 specific inhibitor (Sildenafil) and a general
PDE inhibitor, IBMX. Interestingly, in wild type mice the overall PDE activity may
be contributed primarily by PDE5, as sildenafil and IBMX inhibitions were PDE
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statistically indistinguishable. However, in AGS3-/- mice, the nonspecific PDE
inhibitor (IBMX) provided significantly more PDE inhibition than Sildenafil,
suggesting that one or more other PDEs may be up-regulated in AGS-/- mice. In
summary, PDE activity actually increases in AGS3-/- mice so altered PDE activity
cannot explain the enhanced sGC dependent function observed in the AGS3-/mice.

Figure 14. Phosphodiesterase (PDE) activity in aortic lysates of AGS3-/- and wild
type mice. cGMP [α-32P] was synthesized using purified sGC and was incubated with
mouse aortic lysates in the presence of PBS, specific PDE5 inhibitor Sildenafil, or
nonspecific PDE inhibitor IBMX. Reaction products were separated by TLC on
polyethyleneimine cellulose TLC plates. (A) A representative TLC radiochromatogram
with substrate and product of PDE reaction indicated. (B) PDE activity in aortic lysates of
wild type and AGS3-/- in the presence of vehicle (PBS), Sildenafil or IBMX. Data are
presented as mean +/- SD (n=6). * p<0.05.

sGC Subunit Expression in AGS3-/- Mice - Increased expression of sGC
protein in AGS3-/- also might explain the observed enhancement of the sGCdependent hemodynamic response. To test this, a Western blot analysis was
performed on aortic tissues. The cytosolic fractions expected to contain sGC
were separated by SDS-PAGE and probed with antibodies against the α1 or β1
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subunits of sGC. The results shown in Figure 15A demonstrate that very similar
amounts of the β1 subunit are found in aorta cytosol of both AGS3-/- and wild
type mice. However, substantially less α1 subunit was observed in the aorta from
AGS3-/- mice (Fig. 15A). As translocation of α1 sGC to membrane compartments
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Figure 15. Expression of sGC subunits in AGS3-/- and wild type mice. (A)
Expression of α1 and β1 sGC subunits in cytosolic fractions of AGS3-/- and wild type
aortic lysates was probed by Western blotting using antibodies against α1 and β1 of
sGC subunits. α-actin was used to assess equal loading. (B) α1 sGC does not
translocate to the membranes. High-speed supernatants (Sn) and pellets (P) from
wild type and AGS3-/- aortic tissues were separated by ultracentrifugation and
probed for α1 sGC by Western blotting.

might explain the decrease in the cytosolic α1 levels, we assessed the amounts
of α1 in the membrane fractions. As shown in Figure 15B, α1 proteins was not
observed in the 100,000 x g pellets (membrane fraction) from either wild type or
AGS3-/- aortas. Thus, translocation to the membrane does not occur to any
significant extent and there is actually an overall decrease in α1 protein levels in
aortas of AGS3-/- mice.
Next, we looked for possible differences in transcription in AGS3-/- and
wild type mice that might explain the differences in α1 protein levels between the
mice strains. RT-qPCR was utilized to measure the relative abundance of α1
mRNA in aortic samples from AGS3-/- and wild type mice (Fig 15A). We found
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that wild type and AGS3-/- samples contained comparable levels of α1 sGC
transcript. This means that differences in α1 protein level are not due to
differences in α1 message levels.
Previous reports have noted increased amounts of α2 protein in aortas of
α1 knockout mice (52). Thus, we looked for changes in α2 transcript level in the
AGS3-/- mice. As shown in Figure 16, we found that AGS3-/- mice had essentially
unchanged transcript levels for α1, α2 or β1 sGC subunits. This implies that there
was no compensation of α1 loss through increased transcription and translation
of the α2 sGC subunit in aorta of the AGS3-/- mice. As sGC is an obligate

Figure 16. Level of sGC transcripts in AGS3-/- and wild type mice. Transcript
levels of α1, β1 and α2 were determined by qRT-PCR and normalized to 18S
ribosomal RNA to obtain CT values, where CT = CTtarget – CT18S. Relative fold
change in transcript levels for α1 (A), β1 (B) and α2 (C) were calculated based on
CT values, where CT = CTtarget -CTWT. Dashed line across graph demarcates
equal transcript levels between AGS3-/- and wild type samples. Data are presented as
mean ± SD (n=3).

heterodimer, the observed decrease in α1 protein levels implies a lower amount
of functional sGC in the AGS3 knockout animals. In conclusion, the enhanced
sGC-dependent response observed in AGS3-/- mice is not the result of increased
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sGC expression in these animals.
sGC Activity - Next, we sought to directly assess sGC activity in AGS3-/mice. We measured the accumulation of [32P] cGMP in aortic tissue cytosol
incubated with [α-32P] GTP, in the presence or absence of an NO-donor, DEANO. Similar to the PDE assay, the reaction products were separated by TLC and
the amount of [32P] cGMP formed was quantified. Previously preformed controls
validated the position of GTP, cGMP and GMP along the vertical axis of the TLC
plate (not shown). As expected, DEA-NO increased sGC activity in both AGS3-/and wild type mice (Fig 17A,B). However, we found that the same amount of
AGS3-/- lysate total protein generated more cGMP in response to NO than did the
wild type lysate (Fig. 17A). To take into account the difference in the expression
of functional heterodimeric sGC between AGS3-/- and wild type mice, sGC
conversion rates were normalized to the expression of the α1 subunit and

A
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B NO B NO B NO B NO B NO B NO

cGMP
GDP
GMP

GTP

Percent of wild type sGC ac vity

100 μM 100 μM 100 μM 100 μM 100 μM 100 μM
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*
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200
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wild type aorta
AGS3-/- aorta
AGS3-/WT
Figure 17. sGC activity is elevated in AGS3-/- aorta lysates. GTP [α-32P] was
incubated with equal amounts of wild type and AGS3-/- mouse aortic lysates in the
presence of PBS (B), or 100 μM DEA-NO (NO). Reaction products were
separated on a polyethyleneimine cellulose TLC plate and visualized by
radiography. (A) A representative TLC radiochromatogram with the positions of
substrate (GTP) and product (cGMP) of the sGC reaction indicated. GMP and
putative GDP positions are also indicated. (B) The quantity of cGMP was
determined by densitometry and used to calculate relative sGC activity in wild
type and AGS3-/- mice. Data are presented as mean +/- SD (n=3) *p<0.05.
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reported as the percent of wild type sGC activity. As presented in Figure 17B,
this analysis indicated that relative specific activity of sGC in AGS3-/- mice was
nearly 5 times higher than in the wild type mice. These results strongly indicate
that the absence of AGS3 protein lead to an inherently more active sGC. In
summary, these data clearly are consistent with our hypothesis that AGS3 is a
negative modulator of sGC in vivo.
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DISCUSSION:
As previously mentioned, the NO/sGC/cGMP pathway has significant
cardiovascular implications. Activation of the pathway is known to be beneficial
for atherosclerosis, thrombosis, or stroke patients by inhibiting platelet adhesion
to vascular endothelium (53)and/or by relaxing smooth muscle cells to reduce
blood pressure (54). However, in the pathological state, NO bioavailability is
reduced by its interaction with the increase in abundance of reactive oxygen
species generated by surrounding inflammatory processes (55). As a result, NOdependent activation of sGC is compromised, and unable to mediate
vasodilation. Currently, NO-donors (glyceryl trinitrate, isosorbide nitrates) are
used as pharmacological agents to supplement the loss of endogenous NO
levels that are ultimately thought to mitigate vasoconstriction in patients
experiencing angina (56). Unfortunately, research has shown that these patients
develop tolerance over time, limiting the efficacy of this treatment method (57).
Elevated levels in circulating NO from exogenous treatment sources, react with
local reactive oxygen species to further curb NO availability, and to further
increase oxidative stress (58). Moreover, elevated oxidative stress results in the
oxidation of sGC, rendering it unresponsive to available NO (58). Therefore,
there is a growing need in the clinic for methods that implement NO-independent
activation of sGC to manage cardiovascular diseases. With this category of drug,
oxidative stress stemming from NO-donor treatment could be minimized. The list
of agents that have been identified to activate sGC without the use of NO has
expanded in recent years. Nevertheless, many of these compounds are found to
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be toxic in vivo (59). As a result, alternative for a safe and effective treatment
method for stimulating sGC are needed.
In this study, we show that AGS3 deficiency in mice resulted in increased
duration of sGC-mediated vasodilation compared to wild type mice, which could
be attributed to increased activity of sGC in aorta. These studies describe an
AGS3 function outside its accepted role as a receptor-independent activator of
G-protein signaling, highlighting its action in modulating sGC function.
To gain insight into the possible changes in sGC function, an AGS3
knockout colony was obtained from Dr. Stephen Lanier, whose group generated
these mice. We believed this was a strong approach that allowed us to directly
assess the changes in sGC activity in the absence of endogenous AGS3.
Generating a similar knockout model in fruit flies or yeast would have provided
limited information regarding the effect of AGS3 on sGC.
Once we had confirmed the mice were indeed AGS3 null, we monitored
and compared hemodynamic responses to sGC activators in AGS3-/- and wild
type mice. Administration of either an NO-dependent (DEA-NO) or an NOindependent activator (BAY41-2272) of sGC in AGS3-/- mice resulted in extended
depression in the mean arterial blood pressure as compared to wild type mice.
Our direct measurements of sGC activity indicated that the activity was nearly
five times higher in AGS3-/- mice than in the wild-type counterparts. These results
led us to infer that elevated sGC activity sustains the decrease in the mean
arterial blood pressure. The confluence of results from in vivo blood pressure
monitoring and in vitro biochemical assays in the present study support my
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hypothesis that AGS3 operates as a negative modulator of sGC function. To
ensure that NO-dependent signaling processes function properly, the rise and fall
of intracellular cGMP levels in response to NO should be tightly regulated. AGS3dependent inhibition of sGC may contribute to this regulation.
Unexpectedly, we discovered that AGS3-/- deficient mice express a lower
level of α1 sGC subunit in aorta as compared to their wild-type counterparts.
Although our studies demonstrated that this decrease is not due to changes in α1
transcription, it remains to be determined if the exact cause involves translational
control, ubiquitin-mediated protein degradation, or post-transcriptional regulation
by microRNAs. Secondary to this observation, we were interested in
understanding why the level of β1 sGC subunit protein did not decrease together
with α1. Traditionally, unbound subunits of a larger complex of proteins become
unstable and are targeted for proteolysis. However, our after observation of an
imbalance in sGC subunit expression in aortas of AGS3-/- mice appears to
counter this notion. Literature analysis identified a study by Zabel et al (60),
which tested whether sGC subunits are capable of forming homodimers
intracellularly. They demonstrated that both α1 and β1 subunits form stable
homodimers in the absence of the opposite subunit. It is thus reasonable to
consider that the β subunit of sGC in AGS3-/- mice escapes degradation due to
homodimerization.
The proposed role of AGS3 as a negative modulator of sGC activity has
important implications ifor regulating sGC function. Current regulators of sGC
function that are considered for applications in a clinical setting are NO
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generators, or NO-independent sGC activators targeting an sGC allosteric site.
The existing approaches do not include alternative modes of regulating sGC
function. Namely, little efforts have been focused on identifying and down
regulating endogenously produced agents involved in deactivating sGC. As a
start to filling this gap, we provide evidence that removing AGS3 expression in
vascular smooth muscle tissue results in slower sGC deactivation and more
sustained blood vessel dilation.
The exact mechanism of AGS3-dependent inhibition of sGC remains
uncharacterized. In a previous study conducted by Chauhan and colleagues (46),
it was demonstrated that activated sGC was inhibited in the presence of AGS3. It
remains to be determined whether a direct interaction between sGC and AGS3 is
required. Co-immunoprecipitation experiments with purified proteins might be
conducted to test for direct interaction between AGS3 and sGC. As mentioned
previously, AGS3 is highly similar to LGN protein, a proven direct sGC interactor
(43). Furthermore, that study demonstrated that sGC-LGN interaction results in
inhibition of sGC activity. Mapping the region of interaction between sGC and
LGN revealed that the TPR-containing domain of LGN is sufficient for interaction
with the catalytic domain of sGC (46). Because of the high degree of amino acid
sequence homology (70%) between AGS3 and LGN in the TPR domain (aa 1390), it is reasonable to assume that AGS3 also binds and interacts with sGC at
the catalytic domain to inhibit its function. Elevated sGC activity and function in
AGS3-/- mice may also be explained by increased stability of the sGC-NO
complex. As described above, once NO dissociates from sGC the production of
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cGMP falls to a basal state. In future studies, this hypothesis might be tested by
direct spectroscopic analyses of the stability of sGC-NO complex in the absence
and presence of purified AGS3.
Future studies will also need to be performed to determine whether AGS3
alone is sufficient for sGC deactivation, or if additional cellular factors are
needed. Previous studies demonstrated that AGS3 can bind with more than one
protein simultaneously (42). For example, the GoLoco domain of AGS3 is
capable of binding several Gα subunits to coordinate distinct G-protein signaling
pathways (61). This multivalent action is likely a result of the presence of multiple
GPR motifs in the GoLoco domain. Previous studies also demonstrated that just
one TPR motif is sufficient to mediate protein-protein interactions (62). Thus,
AGS3, which contains seven TPR motifs, may potentially bind seven different
target proteins. The linker region of LGN, located between the TPR and GoLoco
domains, has also been shown to interact with postsynaptic density 95 (PSD95),
synapse-associated protein 102 (SAP 102), and the serine/threonine kinase
LKB1 (63), suggesting that this region of AGS3 may also bind to other proteins.
All together, AGS3 may have the potential to function as a scaffolding protein
and recruit accessory proteins into a larger complex that modulate sGC function.
Further work is needed to determine the exact nature of any protein complex that
associates with sGC. While the present studies revealed the effects of AGS3
deficiency in the vascular function of sGC, it remains to be determined whether
sGC function is affected in other tissues. Of special interest are the lung and
brain tissues, where high level of sGC and AGS3 has been previously
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reported(46,49).
It also remains to be determined whether AGS3 interactions have
additional cellular signaling implications. Originally found to bind and stabilize Gαi
in the GDP state located in the cellular membrane(43), AGS3 effectively
increases the production of cAMP from ATP in the cell. How might recruitment of
AGS3 into a complex with activated sGC affect Gαi signaling? It has been
previously reported that the membrane bound FERM and PDZ domain containing
1 protein (Frmpd1) localizes AGS3 to membrane fractions by its interaction with
the TPR domain of AGS3 (64). These studies demonstrated that upon the cell
receiving a stimulus, AGS3 might switch binding partners, altering the extent of
its association with Gαi. A similar process may be postulated for sGC-AGS3
interaction. Moreover, the putative scaffolding function of AGS3 and its
association with membrane-bound proteins may affect the localization of sGC
among various subcellular locations.
In conclusion, the present studies provide additional support to the
hypothesis that AGS3 protein is a negative modulator of sGC function. While
many aspects of the mechanism of action are not understood, this interaction
may be the basis for a new type of regulation of sGC function in the
cardiovascular system. One can envision a new type of drug that interferes with
the interaction of AGS3 and sGC to modulate the inhibition of sGC by AGS3,
thereby sensitizing the response of sGC to endogenous NO levels. Additionally,
novel therapeutic interventions aimed at dilating blood vessels might be tailored
to increase sGC activity targeted disruption of AGS3.
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